Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report
Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2024-06, Vol.29 (6), p.543-545 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 545 |
|---|---|
| container_issue | 6 |
| container_start_page | 543 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 29 |
| creator | Wang, Huaiyu Fan, Zaiwen Yang, Xiaoming Wu, Qing Jiang, Suxin Zhu, Jingna Liu, Jie Zhou, Chuanhong Liu, Yinghui You, Xia Han, Yong |
| description | Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease. |
| doi_str_mv | 10.1093/oncolo/oyad339 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11144966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A801556169</galeid><sourcerecordid>A801556169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-14b30f66215596156cf87fead2037a2df6ceeaddd39cd41d69934b25fd3589493</originalsourceid><addsrcrecordid>eNptUl1v0zAUjRCIjcErj8gSL7xki2PHiXlBVbWNiopJ7ZB4s1z7JjVK7M5OQP0r_Fpu1TKBNFmyj33PPb5fWfaWFpe0kOwqeBP6cBX22jImn2XntOIy57L4_hxx0bC8ppU8y16l9KMoELLyZXbGmrLgjNXn2e81PEzgR6d7cr1zFuKA6DaGX-OW3GgzhkhWYGB3APf7GJLzQL44rxOQhd-6jUNLvvB2MmDJSltnUGA9xQ7injhP7nrXhQFGnUY9OkO-Bp-v8ZOezAG35eQ7MtfeQPxIZohQdwW7EMfX2YtW9wnenM6L7NvN9f38c768u13MZ8vcMM7GnPINK1ohSlpVUtBKmLapW9C2LFitS9sKA3izlkljObVCSsY3ZdVaVjWSS3aRfTrq7qbNANZgNaLu1S66Qce9Ctqp_y3ebVUXfipKKedSCFT4cFKIAauZRjW4ZDA77SFMSZWSMs7rqmRIfX-kdroH5XwbUNIc6GrWYH8qQcUhpMsnWLgsDM4ED63D96ccDHYoRWgfw6eFOgyKOg6KOg0KOrz7N-lH-t_JYH8AVaS-Dg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2913447523</pqid></control><display><type>article</type><title>Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report</title><source>Oxford Journals Open Access Collection</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Wang, Huaiyu ; Fan, Zaiwen ; Yang, Xiaoming ; Wu, Qing ; Jiang, Suxin ; Zhu, Jingna ; Liu, Jie ; Zhou, Chuanhong ; Liu, Yinghui ; You, Xia ; Han, Yong</creator><creatorcontrib>Wang, Huaiyu ; Fan, Zaiwen ; Yang, Xiaoming ; Wu, Qing ; Jiang, Suxin ; Zhu, Jingna ; Liu, Jie ; Zhou, Chuanhong ; Liu, Yinghui ; You, Xia ; Han, Yong</creatorcontrib><description>Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyad339</identifier><identifier>PMID: 38204337</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Aged ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - surgery ; Care and treatment ; Complications and side effects ; ErbB Receptors - antagonists & inhibitors ; ErbB Receptors - genetics ; Female ; Genetic aspects ; Humans ; Lung cancer, Non-small cell ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Lung Neoplasms - surgery ; Male ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Precision Medicine Clinic: Molecular Tumor Board ; Protein Kinase Inhibitors - therapeutic use ; Tyrosine Kinase Inhibitors</subject><ispartof>The oncologist (Dayton, Ohio), 2024-06, Vol.29 (6), p.543-545</ispartof><rights>The Author(s) 2024. Published by Oxford University Press.</rights><rights>COPYRIGHT 2024 Oxford University Press</rights><rights>The Author(s) 2024. Published by Oxford University Press. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144966/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144966/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38204337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Huaiyu</creatorcontrib><creatorcontrib>Fan, Zaiwen</creatorcontrib><creatorcontrib>Yang, Xiaoming</creatorcontrib><creatorcontrib>Wu, Qing</creatorcontrib><creatorcontrib>Jiang, Suxin</creatorcontrib><creatorcontrib>Zhu, Jingna</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Zhou, Chuanhong</creatorcontrib><creatorcontrib>Liu, Yinghui</creatorcontrib><creatorcontrib>You, Xia</creatorcontrib><creatorcontrib>Han, Yong</creatorcontrib><title>Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.</description><subject>Aged</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - surgery</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>ErbB Receptors - genetics</subject><subject>Female</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - surgery</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Neoplasm Metastasis</subject><subject>Precision Medicine Clinic: Molecular Tumor Board</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Tyrosine Kinase Inhibitors</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUl1v0zAUjRCIjcErj8gSL7xki2PHiXlBVbWNiopJ7ZB4s1z7JjVK7M5OQP0r_Fpu1TKBNFmyj33PPb5fWfaWFpe0kOwqeBP6cBX22jImn2XntOIy57L4_hxx0bC8ppU8y16l9KMoELLyZXbGmrLgjNXn2e81PEzgR6d7cr1zFuKA6DaGX-OW3GgzhkhWYGB3APf7GJLzQL44rxOQhd-6jUNLvvB2MmDJSltnUGA9xQ7injhP7nrXhQFGnUY9OkO-Bp-v8ZOezAG35eQ7MtfeQPxIZohQdwW7EMfX2YtW9wnenM6L7NvN9f38c768u13MZ8vcMM7GnPINK1ohSlpVUtBKmLapW9C2LFitS9sKA3izlkljObVCSsY3ZdVaVjWSS3aRfTrq7qbNANZgNaLu1S66Qce9Ctqp_y3ebVUXfipKKedSCFT4cFKIAauZRjW4ZDA77SFMSZWSMs7rqmRIfX-kdroH5XwbUNIc6GrWYH8qQcUhpMsnWLgsDM4ED63D96ccDHYoRWgfw6eFOgyKOg6KOg0KOrz7N-lH-t_JYH8AVaS-Dg</recordid><startdate>20240603</startdate><enddate>20240603</enddate><creator>Wang, Huaiyu</creator><creator>Fan, Zaiwen</creator><creator>Yang, Xiaoming</creator><creator>Wu, Qing</creator><creator>Jiang, Suxin</creator><creator>Zhu, Jingna</creator><creator>Liu, Jie</creator><creator>Zhou, Chuanhong</creator><creator>Liu, Yinghui</creator><creator>You, Xia</creator><creator>Han, Yong</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240603</creationdate><title>Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report</title><author>Wang, Huaiyu ; Fan, Zaiwen ; Yang, Xiaoming ; Wu, Qing ; Jiang, Suxin ; Zhu, Jingna ; Liu, Jie ; Zhou, Chuanhong ; Liu, Yinghui ; You, Xia ; Han, Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-14b30f66215596156cf87fead2037a2df6ceeaddd39cd41d69934b25fd3589493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - surgery</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>ErbB Receptors - genetics</topic><topic>Female</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - surgery</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Neoplasm Metastasis</topic><topic>Precision Medicine Clinic: Molecular Tumor Board</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Tyrosine Kinase Inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Huaiyu</creatorcontrib><creatorcontrib>Fan, Zaiwen</creatorcontrib><creatorcontrib>Yang, Xiaoming</creatorcontrib><creatorcontrib>Wu, Qing</creatorcontrib><creatorcontrib>Jiang, Suxin</creatorcontrib><creatorcontrib>Zhu, Jingna</creatorcontrib><creatorcontrib>Liu, Jie</creatorcontrib><creatorcontrib>Zhou, Chuanhong</creatorcontrib><creatorcontrib>Liu, Yinghui</creatorcontrib><creatorcontrib>You, Xia</creatorcontrib><creatorcontrib>Han, Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Huaiyu</au><au>Fan, Zaiwen</au><au>Yang, Xiaoming</au><au>Wu, Qing</au><au>Jiang, Suxin</au><au>Zhu, Jingna</au><au>Liu, Jie</au><au>Zhou, Chuanhong</au><au>Liu, Yinghui</au><au>You, Xia</au><au>Han, Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2024-06-03</date><risdate>2024</risdate><volume>29</volume><issue>6</issue><spage>543</spage><epage>545</epage><pages>543-545</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Sequential regimens in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) can overcome tyrosine kinase inhibitor (TKI) resistance and maximize clinical benefit. Patients with advanced NSCLC can achieve excellent tumor control after a period of EGFR-TKI treatment. Patients may benefit from additional local treatment, such as surgery or radiation therapy, once the tumor is under control. Here, we present a case of a patient with advanced oligometastatic NSCLC with EGFR mutations who achieved downstaging through sequential EGFR-TKI-based precision medicine allowing resection of residual disease.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>38204337</pmid><doi>10.1093/oncolo/oyad339</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2024-06, Vol.29 (6), p.543-545 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11144966 |
| source | Oxford Journals Open Access Collection; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Aged Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - surgery Care and treatment Complications and side effects ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Female Genetic aspects Humans Lung cancer, Non-small cell Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - surgery Male Middle Aged Mutation Neoplasm Metastasis Precision Medicine Clinic: Molecular Tumor Board Protein Kinase Inhibitors - therapeutic use Tyrosine Kinase Inhibitors |
| title | Sequential Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Induced Radical Surgery in Oligometastatic Non-Small Cell Lung Cancer: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A20%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sequential%20Epidermal%20Growth%20Factor%20Receptor%20Tyrosine%20Kinase%20Inhibitor-Induced%20Radical%20Surgery%20in%20Oligometastatic%20Non-Small%20Cell%20Lung%20Cancer:%20A%20Case%20Report&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Wang,%20Huaiyu&rft.date=2024-06-03&rft.volume=29&rft.issue=6&rft.spage=543&rft.epage=545&rft.pages=543-545&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyad339&rft_dat=%3Cgale_pubme%3EA801556169%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2913447523&rft_id=info:pmid/38204337&rft_galeid=A801556169&rfr_iscdi=true |